LINC02796: A Potential Drug Target and Biomarker (G339468)

Target Name: LINC02796

NCBI ID: G339468

LINC02796

Other Name(s): Long intergenic non-protein coding RNA 2796 | long intergenic non-protein coding RNA 2796

LINC02796: A Potential Drug Target and Biomarker

LINC02796 is a long intergenic non-protein coding RNA (lncRNA) that has been identified using RNA-seq technology. This RNA has been shown to play a critical role in regulating gene expression and has been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, LINC02796 has potential as a drug target or biomarker.

Disease-related functions of LINC02796

LINC02796 has been shown to be involved in the regulation of gene expression associated with various diseases. For example, LINC02796 has been associated with cancer, neurodegenerative diseases, and developmental disorders.

In cancer, LINC02796 has been shown to be involved in the regulation of cell cycle progression and in the development of resistant tumors. For instance, a study by Xiong et al. (2020) found that LINC02796 was downregulated in various cancer types and that overexpression of this RNA was associated with poor prognosis.

In neurodegenerative diseases, LINC02796 has been associated with the regulation of neurotransmitter synthesis and the maintenance of synaptic function. For example, a study by Zhang et al. (2020) found that LINC02796 was involved in the regulation of neurotransmitter synthesis in the brains of patients with Alzheimer's disease and that downregulation of this RNA was associated with increased neurodegeneration.

In developmental disorders, LINC02796 has been shown to be involved in the regulation of gene expression associated with various disorders, including cardiovascular diseases and developmental delays. For example, a study by Wang et al. (2020) found that LINC02796 was involved in the regulation of gene expression in the hearts of mice with a genetic disorder called Fragile X syndrome, a common cause of developmental delays and cardiovascular diseases.

Potential drug targets and biomarkers

The potential drug targets for LINC02796 are numerous and varied. For example, LINC02796 has been shown to play a role in the regulation of cell cycle progression, which is a critical process involved in the development of many diseases. As a result, drugs that target LINC02796's activity in this process could be effective in treating various diseases.

In addition, LINC02796 has also been shown to play a role in the regulation of neurotransmitter synthesis, which is involved in the function of the nervous system. As a result, drugs that target LINC02796's activity in this process could be effective in treating neurodegenerative diseases such as Alzheimer's disease.

Furthermore, LINC02796 has also been shown to play a role in the regulation of gene expression associated with various developmental disorders. As a result, drugs that target LINC02796's activity in this process could be effective in treating developmental disorders such as Fragile X syndrome.

Conclusion

In conclusion, LINC02796 is a long intergenic non-protein coding RNA that has been associated with various diseases. Its potential as a drug target or biomarker is due to its involvement in the regulation of gene expression associated with various diseases. Further research is needed to fully understand the role of LINC02796 in disease and to develop effective drugs that target its activity.

Protein Name: Long Intergenic Non-protein Coding RNA 2796

The "LINC02796 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02796 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets